Lv31
330 积分 2021-07-05 加入
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
14天前
已完结
Perioperative Nivolumab in Resectable Lung Cancer
14天前
已完结
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
14天前
已完结
Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy
28天前
已完结
Adjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoadjuvant Immunotherapy
29天前
已完结
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
1个月前
已关闭
Consensus on the lung cancer management after third-generation EGFR-TKI resistance
1个月前
已完结
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
1个月前
已完结
Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies
3个月前
已完结
Lung cancer in China: current and prospect
4个月前
已完结
皖公网安备34019202002308
